Improvement of the evaluation method for teratogenicity using zebrafish embryos

Area of Science:

• Developmental toxicology
• Pharmacology
• Animal models in drug discovery

Background:

• Zebrafish are valuable for drug discovery due to their rapid development, transparency, and similarities to mammalian development.
• Their small size and in vitro culture suitability facilitate high-throughput teratogenicity screening.
• Existing methods require improvements for higher throughput and prediction accuracy.

Purpose of the Study:

• To enhance the evaluation method for teratogenicity of test compounds using zebrafish embryos.
• To develop a high-throughput and high-prediction rate assay for early-stage drug discovery.
• To refine teratogenicity assessment by modifying existing zebrafish embryo protocols.

Main Methods:

• A modified zebrafish assay using non-dechorionated embryos and limited parameter observation was established.
• Embryos were exposed to test compounds during the organogenesis period (5-6 to 144 hours post-fertilization).
• Morphological and functional abnormalities were assessed at 11 endpoints to determine teratogenicity potential.

Main Results:

• The improved assay achieved a 90% prediction rate (53/59 compounds) for known teratogenic and non-teratogenic compounds.
• Low false negative and false positive rates were observed during validation.
• The method demonstrated high throughput capability and predictive accuracy.

Conclusions:

• The improved zebrafish teratogenicity evaluation method is a valuable tool for early drug discovery screening.
• This assay offers a reliable and efficient approach for identifying potential developmental toxicants.
• The findings support the use of zebrafish as a predictive model for human developmental toxicity.